Paper
8 January 2024 Application and optimization strategy of CAR-NK in AML
Xiwen Hu
Author Affiliations +
Proceedings Volume 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023); 129241Y (2024) https://doi.org/10.1117/12.3013174
Event: 3rd International Conference on Biological Engineering and Medical Science (ICBioMed2023), 2023, ONLINE, United Kingdom
Abstract
In recent years, the application of immunotherapy in the field of cancer has received increasing attention, especially the new precision cellular immunotherapy CAR-T. Although CAR-T Cell therapy has made great achievements in the field of tumor treatment, it seems to show a stagnant phenomenon in the treatment of blood cancer, especially acute myeloid leukemia (AML). However, the emergence of a promising optimization scheme to CAR-T Cell therapy, CAR-NK Cell therapy, seems to break this dilemma. In terms of AML treatment, compared with CAR-T Cell therapy, CAR-NK are safer, more effective and more economical. However, it still has some shortcomings that need improvement, such as how to quickly and in bulk obtain NK cells and how to improve the effect of in vivo action. This paper discusses the benefits of CAR-NK Cell therapy compared with CAR-T Cell therapy, the application status in the AML field, the shortcomings of the method and the solutions, with AML as an example. The purpose is to apply such a very potential treatment method to more refractory diseases and benefit more patients as soon as possible.
(2024) Published by SPIE. Downloading of the abstract is permitted for personal use only.
Xiwen Hu "Application and optimization strategy of CAR-NK in AML", Proc. SPIE 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023), 129241Y (8 January 2024); https://doi.org/10.1117/12.3013174
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Cancer

Tumors

Blood

Oncology

Chemotherapy

In vivo imaging

Leukemia

Back to Top